NCT03903562 2026-04-06
V503-024
Merck Sharp & Dohme LLC
Phase 3 Completed
Clinical Trials
59 trialsNCT05119855 2026-02-05
Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01302834 2026-01-12
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT04772534 2025-05-30
V503-066
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02135419 2024-07-26
ANCHOR
AIDS Malignancy Consortium
Phase 3 Completed
NCT00380367 2023-05-31
Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00943722 2022-10-03
A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00481767 2020-11-17
Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age.
GlaxoSmithKline
Phase 3 Completed
NCT00947115 2020-10-30
Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects
GlaxoSmithKline
Phase 3 Completed
NCT01164722 2020-08-04
Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia
AIDS Malignancy Consortium
Phase 3 Completed
NCT01381575 2020-06-09
Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls
GlaxoSmithKline
Phase 3 Completed
NCT01627561 2020-04-10
Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old
GlaxoSmithKline
Phase 3 Completed
NCT03546842 2020-02-25
V503-017
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00877877 2020-01-18
Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects.
GlaxoSmithKline
Phase 3 Completed
NCT00637195 2020-01-03
Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)
GlaxoSmithKline
Phase 3 Completed
NCT00250276 2020-01-02
Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation.
GlaxoSmithKline
Phase 3 Completed
NCT00294047 2020-01-02
Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older
GlaxoSmithKline
Phase 3 Completed
NCT00423046 2020-01-02
Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age
GlaxoSmithKline
Phase 3 Completed
NCT00196937 2019-12-11
Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18
GlaxoSmithKline
Phase 3 Completed
NCT03158220 2019-11-21
Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01462357 2019-11-15
Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females
GlaxoSmithKline
Phase 3 Completed
NCT01249365 2019-11-13
The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study
GlaxoSmithKline
Phase 3 Completed
NCT01190176 2019-10-30
Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects
GlaxoSmithKline
Phase 3 Completed
NCT00937950 2019-10-29
Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study Subjects
GlaxoSmithKline
Phase 3 Completed
NCT01190189 2019-06-19
Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study
GlaxoSmithKline
Phase 3 Completed
NCT00779766 2019-06-10
Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects
GlaxoSmithKline
Phase 3 Completed
NCT00834106 2019-02-04
Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00988884 2018-12-14
A Study of V503 Given Concomitantly With Menactraâ„¢ and Adacelâ„¢ in 11 to 15 Year Olds (V503-005)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01254643 2018-11-28
A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008).
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00543543 2018-11-27
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01073293 2018-11-27
A Study of V503 Vaccine Given Concomitantly With REPEVAXâ„¢ in 11 to 15 Year Olds (V503-007)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01245764 2018-11-14
GARDASILâ„¢ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02114385 2018-11-01
A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00492544 2018-09-04
Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age
GlaxoSmithKline
Phase 3 Completed
NCT00122681 2018-08-20
Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18
GlaxoSmithKline
Phase 3 Completed
NCT00578227 2018-08-17
Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects
GlaxoSmithKline
Phase 3 Completed
NCT00652938 2018-08-17
Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects
GlaxoSmithKline
Phase 3 Completed
NCT00996125 2018-08-17
Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299 Vaccine in Healthy Female Subjects
GlaxoSmithKline
Phase 3 Completed
NCT01277042 2018-08-17
Study to Assess Immune Responses and Safety of the GSK-580299 Vaccine in Healthy Women (26 to 45 Years)
GlaxoSmithKline
Phase 3 Completed
NCT01984697 2018-08-08
V503-010
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00344032 2018-07-20
Evaluation of the Immune and Safety Response of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine in Healthy Indian Women
GlaxoSmithKline
Phase 3 Completed
NCT00345878 2018-07-20
Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years
GlaxoSmithKline
Phase 3 Completed
NCT00369824 2018-07-20
Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects
GlaxoSmithKline
Phase 3 Completed
NCT00426361 2018-07-20
Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects
GlaxoSmithKline
Phase 3 Completed
NCT00485732 2018-07-20
A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years
GlaxoSmithKline
Phase 3 Completed
NCT00799825 2018-07-12
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
GlaxoSmithKline
Phase 3 Completed
NCT01418937 2018-07-12
Safety Evaluation of a Human Papillomavirus (HPV) Vaccine in Healthy Female Control Subjects From the GSK HPV 023 Study
GlaxoSmithKline
Phase 3 Completed
NCT00552279 2018-06-25
Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age
GlaxoSmithKline
Phase 3 Completed
NCT00092547 2018-02-20
A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00090220 2017-04-21
A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019)
Merck Sharp & Dohme LLC
Phase 3 Completed